NCT05742230View on ClinicalTrials.gov

Effect of Henagliflozin on Cardiac Function in Type 2 Diabetes Patients With Chronic Heart Failure (HERO-HF)

NARecruitingINTERVENTIONAL
Enrollment

1,932

Participants

Timeline

Start Date

April 15, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

December 31, 2025

Conditions
Heart Failure
Interventions
DRUG

Henagliflozin 10 mg

Participants will receive 10 mg single oral tablets orally once daily.

DRUG

blank control

standard treatment

Trial Locations (1)

Unknown

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER